In November 2002, a small group of scientists gathered at the University of Kansas with one clear mission. The topic at hand: an industrial chemical called n-propyl bromide, or nPB. Their goal, according to the conference agenda and meeting notes, was to design a “research program needed to establish nPB as a safe product.”

“It was clear almost from the beginning that the meeting was not about science,” said Kim Boekelheide, an attendee of the conference and a pathology professor from Brown University. Three days after the conference, Boekelheide wrote a letter to the Kansas researchers asking that his name “not be used in any documents prepared or submitted regarding this activity.”